{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:43:30Z","timestamp":1788871410369,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.yebeh.2011.07.035","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T03:16:52Z","timestamp":1315365412000},"page":"499-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Adjunctive lacosamide in clinical practice: Sodium blockade with a difference?"],"prefix":"10.1016","volume":"22","author":[{"given":"Linda J.","family":"Stephen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2011.07.035_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","article-title":"The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels","volume":"73","author":"Errington","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0015","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","article-title":"Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial","volume":"10","author":"Shaibani","year":"2009","journal-title":"J Pain"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Von Elm","year":"2007","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0040","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"Zwarenstein","year":"2008","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate?","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0055","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0060","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1046\/j.1528-1157.2001.02101.x","article-title":"A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy","volume":"42","author":"Wong","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0065","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical data grouped by mechanisms of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2010.10.002","article-title":"Lacosamide neurotoxicity with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?","volume":"20","author":"Novy","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0075","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yebeh.2009.07.043","article-title":"Six months of postmarketing experience with adjunctive lacosmide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany","volume":"16","author":"Wehner","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs: rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0085","series-title":"Presented at: 8th European Congress of Epileptology, Berlin","article-title":"Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice","author":"Shandra","year":"2008"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yebeh.2010.01.016","article-title":"A prospective audit of adjunctive zonisamide in an everyday clinical setting","volume":"17","author":"Stephen","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0095","unstructured":"Brodie MJ, Barry SJ, Bamagous GA, Norrie, JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology, submitted."},{"key":"10.1016\/j.yebeh.2011.07.035_bb0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0105","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0110","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B* 1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0115","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A* 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0120","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"L\u00f6scher","year":"1999","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00228121","article-title":"Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture","volume":"81","author":"Zona","year":"1990","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00228395","article-title":"Valproate and sodium currents in cultured hippocampal neurons","volume":"93","author":"Berg","year":"1993","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0145","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0920-1211(98)00060-6","article-title":"Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons","volume":"32","author":"Taverna","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2011.07.035_bb0150","series-title":"Mechanisms of action of antiepileptic drugs","first-page":"43","article-title":"Voltage-dependent sodium channels","author":"White","year":"2010"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505011004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505011004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:22:47Z","timestamp":1761502967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505011004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1525505011004458"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2011.07.035","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive lacosamide in clinical practice: Sodium blockade with a difference?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2011.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}